Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8540599 | 1.00 | TP53 (0.42) | TP53PDE4BTSHRCA12CA1 | |
| SCHEMBL8540595 | 1.00 | TP53 (0.42) | TP53PDE4BTSHRCA12CA1 | |
| SCHEMBL1316275 | 0.88 | TP53 (0.48) | TP53TSHRHRH3CYP2D6RORC | |
| SCHEMBL15262870 | 0.83 | TP53 (0.34) | TP53 | |
| SCHEMBL6840236 | 0.82 | TP53 (0.47) | TP53PDE4BTSHRHRH3CYP2D6 | |
| SCHEMBL17642608 | 0.82 | TP53 (0.47) | TP53PDE4BTSHRHRH3CYP2D6 | |
| SCHEMBL19596731 | 0.80 | TP53 (0.46) | TP53PDE4BTSHRHRH3CYP2D6 | |
| SCHEMBL1108992 | 0.78 | CHRM4 (0.38) | HRH3CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL1928299 | 0.78 | CHRM4 (0.38) | HRH3CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL21937889 | 0.77 | TP53 (0.40) | TP53PDE4BTSHRHRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3722298-B1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC (KR) | 2023-08-02 | — | — | EP | disclosed |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | OSCOTEC INC. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC. (KR) | 2021-11-25 | — | — | US | disclosed |
| EP-3722298-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | Oscotec Inc. (KR) | 2020-10-14 | — | — | EP | disclosed |
| EP-2803664-B1 | TETRAHYDROBENZOFURANE DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI MEDICINE CO (CN) | 2018-11-21 | — | — | EP | disclosed |
| EP-2683687-B1 | HETEROCYCLIC DERIVATIVES CONTAINING PRIMARY AMINO GROUPS AND DIAZENIUMDIOLATES | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2855419-B1 | NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-2831053-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2831053-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2831064-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-17 | — | — | EP | disclosed |
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | Watson Pharma Private Limited (IN) | 2011-06-16 | — | — | US | disclosed |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | MERLI VALERIANO | 2009-06-18 | — | — | US | disclosed |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-7442806-B2 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-28 | — | — | US | disclosed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| US-5770611-A | Indole derivatives as 5HT1 -like agonists | PFIZER INC. (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0785933-B1 | INDOLE DERIVATIVES AS 5HT1-LIKE AGONISTS | PFIZER LTD (GB) | 1998-03-11 | — | — | EP | disclosed |
| EP-0785933-A1 | INDOLE DERIVATIVES AS 5HT1-LIKE AGONISTS | Pfizer Limited (GB) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011195-A1 | INDOLE DERIVATIVES AS 5HT1-LIKE AGONISTS | PFIZER LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | TP53 3351/4885PDE4B 772/4885TSHR 656/4885 |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | LRRK2, PARK7, WEE1 | TP53 1144/4885PDE4B 1102/4885TSHR 4304/4885 |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | LRRK2, PARK7, PAK3 | TP53 759/4885PDE4B 780/4885TSHR 4342/4885 |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | TP53 3679/4885PDE4B 1879/4885TSHR 353/4885 |
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | OPRL1, OPRD1, OPRK1 | TP53 4793/4885PDE4B 2024/4885TSHR 91/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | TP53 3679/4885PDE4B 1879/4885TSHR 353/4885 |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | OPRL1, AVPR2, AVPR1B | TP53 3679/4885PDE4B 1879/4885TSHR 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.